Compare Core Scientific Inc (CORZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Core Scientific IncTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Core Scientific Inc vs Neurocrine Biosciences Inc — how do they compare? Core Scientific Inc trades at $20.39 (market cap $6.25B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.7× Core Scientific Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.

	CORZ	NBIX
Market Cap	$6.25B	$16.76B
Sector	Technology	Health
52-Week High	$29.16	$185.50
52-Week Low	$13.55	$123.10
Enterprise Value	$8.78B	$16.78B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core Scientific Inc

Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.

While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CORZ

Neocloud stocks rise as NVIDIA-led $500B AI financing plan boosts data center buildout prospects24/7 Wall Street · 18 hours agoBullish CoreWeave Q2 earnings expected in line; Jefferies eyes founder stock sales as next catalyst, profit gains months awayProactive Investors · 19 hours agoBullish TeraWulf leads AI infrastructure stocks in 2026 with a 40.82% gain, driven by a major Anthropic lease deal.24/7 Wall Street · 1 day agoBullish View details →

NBIX

Neurocrine starts Phase 1 trial for new obesity drug NBIP-'1968 targeting multiple metabolic pathways.PRNewsWire · 4 days agoBullish View details →

About Core Scientific Inc

Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.